Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sobi On The Look-Out For Licensing, M&A Opportunities

Executive Summary

Swedish Orphan Biovitrum AB may be in a launch phase with first sales of its long-acting hemophilia products in Europe, but the company is already looking ahead to use its growing commercial capabilities for other products.

Advertisement

Related Content

SOBI North America Is Shopping For Growth
Hemophilia And Rare Diseases Drive European Mid-Pharmas Sobi And Recordati
PIPELINE WATCH – Eight Approvals, Five Orphan Designations And One Filing
Biogen Backs Out Of Hemophilia, But Who Benefits?

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC096921

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel